Jatenzo Manufacturing, Supply & Shortage History

How Jatenzo Works: The Lymphatic Absorption Pathway

Jatenzo's mechanism differs from every injectable and transdermal testosterone product on the US market. The active molecule, testosterone undecanoate, is dissolved in a lipid-based self-emulsifying drug delivery system (SEDDS) inside a soft gelatin capsule. When taken with a meal containing at least 30% fat, the lipid vehicle triggers chylomicron formation in intestinal enterocytes, which channels the drug into the thoracic duct and systemic circulation through the lymphatic system rather than the hepatic portal vein.

This bypass of first-pass liver metabolism is what separates oral TU from the older oral androgen 17-alpha-methyltestosterone, which the Endocrine Society's 2018 guideline explicitly warned against due to hepatotoxicity. By avoiding that hepatic hit, Jatenzo achieves therapeutic serum testosterone concentrations (300-1 to 000 ng/dL) without the liver enzyme elevations seen with methylated androgens.

The pharmacokinetic profile peaks at approximately 5 hours post-dose and requires twice-daily administration to maintain stable levels. In the key trial by Swerdloff et al. (N=166), 87% of men with hypogonadism achieved a mean 24-hour serum testosterone within the eugonadal range after dose titration over 12 weeks [1]. The C_avg was 489 ng/dL at the 237 mg twice-daily starting dose [1]. This is not a slow-release depot. The capsule empties rapidly, and the SEDDS formulation must self-emulsify in the gut within minutes to function correctly.

That requirement places strict demands on manufacturing consistency. Batch-to-batch variation in the lipid excipient blend can shift bioavailability by 20-40%, making the manufacturing process for Jatenzo far more sensitive than that of a standard oral tablet.

Tolmar Pharmaceuticals: The Manufacturing Entity

Tolmar Pharmaceuticals, headquartered in Fort Collins, Colorado, holds the New Drug Application (NDA 206089) for Jatenzo. The company originally developed the formulation as Clarus Therapeutics, which received FDA approval on March 27, 2019. Clarus Therapeutics went public via SPAC merger in late 2021, but filed for Chapter 11 bankruptcy in September 2023. Tolmar acquired the Jatenzo assets out of bankruptcy proceedings.

This ownership transition created a tangible gap in supply continuity. Bankruptcy-related disruptions affected production scheduling, raw material procurement contracts, and distribution agreements with specialty pharmacies. The transition period between Clarus's insolvency and Tolmar's assumption of manufacturing responsibility lasted several months.

Tolmar operates FDA-registered facilities in Colorado and has contract manufacturing partnerships. The soft gelatin encapsulation process for SEDDS formulations requires specialized equipment (rotary die encapsulation lines) that not every contract manufacturer possesses. This limits the number of qualified production sites and creates a manufacturing bottleneck that differs from standard oral solid dose drugs.

The active pharmaceutical ingredient (API), testosterone undecanoate, is sourced from qualified suppliers and must meet USP monograph standards. The lipid excipients in the SEDDS vehicle (which include oleic acid, castor oil, and related medium-chain triglycerides) must also meet pharmaceutical-grade specifications. Any disruption in excipient supply directly impacts capsule production, because the formulation cannot be reformulated without a supplemental NDA filing.

FDA Shortage History and Supply Chain Events

The FDA Drug Shortage Database has documented intermittent availability issues with Jatenzo since its launch. These shortages have occurred for distinct reasons at different points in the product's history.

2019-2020: Launch-phase constraints. Initial commercial production scaled slowly. Clarus Therapeutics operated with limited manufacturing capacity and a single-source supply chain for the SEDDS encapsulation process. Specialty pharmacy distribution added a layer of complexity, as Jatenzo was not stocked at standard retail pharmacies during this period. Patients reported fill delays of 7-14 days during the first year post-launch.

2021-2022: Demand-driven tightness. Prescribing volume grew as awareness of oral TU expanded in the men's health and telehealth markets. According to IQVIA prescription data, oral testosterone prescriptions increased approximately 35% year-over-year between Q3 2020 and Q3 2022. Manufacturing capacity had not expanded proportionally.

2023: Bankruptcy disruption. Clarus Therapeutics' Chapter 11 filing in September 2023 was the most significant supply event. Court filings indicated the company had approximately $40 million in debt against declining revenue. During the bankruptcy process, raw material vendors required cash-on-delivery terms rather than standard net-30 payment, further constraining production.

2024-2025: Tolmar transition and stabilization. Tolmar's acquisition brought fresh capital and existing pharmaceutical manufacturing infrastructure. Production resumed at a higher throughput, and by mid-2024, the FDA shortage listing was resolved. Tolmar expanded distribution beyond specialty pharmacy channels to include select retail and mail-order pharmacies.

The supply chain for Jatenzo remains inherently more fragile than that of generic injectable testosterone cypionate, which has multiple ANDA-approved manufacturers. Jatenzo has no FDA-approved generic equivalent as of May 2026, meaning any production disruption at Tolmar's facilities or its contract partners creates a single point of failure.

How Jatenzo Manufacturing Differs from Injectable Testosterone

Manufacturing injectable testosterone cypionate or enanthate involves dissolving crystalline testosterone ester in cottonseed or sesame oil, sterile-filling vials, and terminally sterilizing or aseptically processing them. Dozens of generic manufacturers hold ANDAs for these products. Cost per vial at wholesale is $15-30 for a month's supply.

Jatenzo's process is categorically different. The SEDDS formulation requires precise blending of lipid excipients at controlled temperatures, followed by encapsulation in soft gelatin shells on rotary die equipment. Each capsule must contain a measured dose dissolved uniformly in the lipid matrix. According to the FDA chemistry review for NDA 206089, dissolution testing for Jatenzo uses a two-stage protocol (acid then buffer) to simulate gastric and intestinal conditions, and batches failing dissolution specifications must be discarded entirely.

Soft gelatin capsule manufacturing also has environmental sensitivity. Humidity above 60% during encapsulation causes shell defects. Temperature excursions during storage can cause the SEDDS vehicle to phase-separate, rendering the capsule bioinequivalent. These factors explain why Jatenzo's shelf life is 36 months when stored at 20-25°C and why the label warns against exposure to temperatures above 30°C.

By contrast, testosterone cypionate in oil is stable for years at room temperature and tolerates wider storage conditions. The manufacturing complexity gap translates directly into a price gap: Jatenzo's wholesale acquisition cost exceeds $600/month versus <$50/month for generic injectable testosterone cypionate, per GoodRx and CMS pricing data.

Regulatory Considerations: No REMS, but Post-Market Commitments

Unlike Aveed (injectable testosterone undecanoate), which carries a Risk Evaluation and Mitigation Strategy requiring administration in certified healthcare settings due to pulmonary oil microembolism risk, Jatenzo was approved without a REMS. This was a deliberate regulatory distinction. The oral route eliminates the risk of post-injection adverse reactions that prompted Aveed's restricted distribution.

The FDA did require post-marketing commitments from the original sponsor, including a cardiovascular outcomes study consistent with the 2015 FDA advisory requiring all testosterone products to carry a warning about potential cardiovascular risk. The Traverse trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement therapy was noninferior to placebo for major adverse cardiovascular events (MACE) over a median follow-up of 33 months [2]. This trial enrolled men receiving various testosterone formulations, and its findings apply broadly to TRT products including Jatenzo.

Post-marketing safety surveillance through the FDA Adverse Event Reporting System (FAERS) has shown that Jatenzo's adverse event profile is consistent with its labeled warnings: polycythemia (hematocrit elevation), increased blood pressure (systolic BP rose 3-5 mmHg on average in the key trial), and lipid changes including HDL reduction of approximately 4 mg/dL [1]. No hepatotoxicity signals have emerged, supporting the lymphatic absorption mechanism's liver-sparing profile.

Raw Material Sourcing and API Supply

Testosterone undecanoate API is manufactured by several global suppliers, primarily in India and China, under FDA Drug Master File (DMF) registrations. The synthesis involves esterification of testosterone with undecanoic acid, producing a long-chain fatty acid ester that is lipophilic enough to partition into chylomicrons during intestinal absorption.

The global API supply for testosterone undecanoate is shared across multiple finished dosage form manufacturers. Nebido (Bayer's injectable TU) and generic injectable TU products in Europe and Asia also consume the same API. When demand surges for any one finished product or when a major API facility undergoes FDA inspection-related shutdowns, the ripple effect can reach Jatenzo's supply chain.

The lipid excipients present a less obvious but equally real vulnerability. Pharmaceutical-grade oleic acid and castor oil derivatives are produced by a small number of specialty chemical companies. Supply disruptions due to crop failures (castor beans are primarily grown in India), geopolitical trade restrictions, or quality failures at excipient manufacturers have all contributed to soft gelatin capsule supply issues across the pharmaceutical industry.

Current Availability and Patient Access

As of May 2026, Jatenzo is actively manufactured and available through specialty and select retail pharmacies in the United States. Tolmar has expanded the distribution network compared to the Clarus era. Patients can verify current availability through the FDA drug shortage database or by contacting Tolmar's patient services line.

Insurance coverage remains inconsistent. Many commercial payers classify Jatenzo as a non-preferred brand and require prior authorization with step therapy through generic injectable testosterone first. The Endocrine Society's 2018 clinical practice guideline does not preferentially recommend any specific testosterone formulation, leaving payer decisions to cost considerations. Jatenzo's list price of over $600/month, compared to <$50/month for generic injectable testosterone cypionate, makes formulary placement challenging.

Tolmar offers a manufacturer copay assistance program that reduces out-of-pocket costs to $75/month for eligible commercially insured patients. Uninsured patients may qualify for patient assistance programs, though availability of these programs changes periodically.

For prescribers managing patients currently on Jatenzo, monitoring serum total testosterone 3-5 hours post-morning-dose (to capture the approximate C_max window) and checking hematocrit and blood pressure at 3 and 6 months, then annually, aligns with the AUA/Endocrine Society recommendations [3]. Dose titration to the 158 mg or 396 mg twice-daily strength should target a serum testosterone between 300 and 1 to 000 ng/dL on mid-dose-interval sampling.